✦ LIBER ✦

Role of Glycosylation in Conformational Stability, Activity, Macromolecular Interaction and Immunogenicity of Recombinant Human Factor VIII

✍ Scribed by Matthew P. Kosloski; Razvan D. Miclea; Sathy V. Balu-Iyer

Book ID: 111767574
Publisher: American Association of Pharmaceutical Scientists
Year: 2009
Tongue: English
Weight: 195 KB
Volume: 11
Category: Article
ISSN: 1550-7416
DOI: 10.1208/s12248-009-9119-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Influence of aggregation on immunogenici

Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice

✍ Vivek S. Purohit; C. Russell Middaugh; Sathyamangalam V. Balasubramanian 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB

Recombinant human factor VIII (rFVIII), a multidomain glycoprotein is used in replacement therapy for treatment of hemophilia A. Unfortunately, 15%-30% of the treated patients develop inhibitory antibodies. The pathogenesis of antibody development is not completely understood. The presence of aggreg

Comparative immunogenicity of recombinan

Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII

✍ E. T. Parker; H. N. Craddock; R. T. Barrow; P. Lollar 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 244 KB

Recombinant Factor VIII SQ—Stability of

Recombinant Factor VIII SQ—Stability of VIII: C in Homogenates from Porcine, Monkey and Human Subcutaneous Tissue

✍ ANGELICA FATOUROS; YLVA LIDÉN; BRITA SJÖSTRÖM 📂 Article 📅 2000 🏛 Pharmaceutical Press 🌐 English ⚖ 492 KB

Effect of route of administration of hum

Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice

✍ Aaron Peng; Puneet Gaitonde; Matthew P. Kosloski; Razvan D. Miclea; Prashant Var 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB

Factor VIII is a multi-domain glycoprotein and is an essential cofactor in the blood coagulation cascade. Its deficiency or dysfunction causes Hemophilia A, a bleeding disorder. Replacement using exogenous recombinant Factor VIII (FVIII) is the first line of therapy for Hemophilia A. Immunogenicity,

Phosphatidylserine containing liposomes

Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A

✍ Karthik Ramani; Razvan D. Miclea; Vivek S. Purohit; Donald E. Mager; Robert M. S 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 257 KB

Factor VIII (FVIII) is a multidomain protein that is deficient in hemophilia A, a clinically important bleeding disorder. Replacement therapy using recombinant human FVIII (rFVIII) is the main therapy. However, approximately 15-30% of patients develop inhibitory antibodies that neutralize rFVIII act

Downregulation of CD40 signal and induct

Downregulation of CD40 signal and induction of TGF-β by phosphatidylinositol mediates reduction in immunogenicity against recombinant human Factor VIII

✍ Puneet Gaitonde; Aaron Peng; Robert M. Straubinger; Richard B. Bankert; Sathy V. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 332 KB

Factor VIII (FVIII) is an important coagulation cofactor and its deficiency causes Hemophilia A, a bleeding disorder. Replacement therapy using recombinant FVIII is currently the first line of therapy for Hemophilia A, but the development of neutralizing antibody is a major clinical complication for